( December 10, 2024, 2:41 PM EST) -- WASHINGTON, D.C. — A panel in the Federal Circuit U.S. Court of Appeals said that a Third Circuit judge overseeing district court proceedings in Delaware was correct to hold that a defendant biopharmaceutical company’s abbreviated new drug application (ANDA) did not infringe the plaintiff company’s patents on medications for the skin condition called rosacea....